119,500.00
-2700(-2.21%)
Currency In KRW
Address
#1014 Gwanggyo Ace Tower1, 17
Suwon-si, 16226
Korea, Republic of
Phone
82 3 1779 8400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
72
First IPO Date
July 18, 2018
| Name | Title | Pay | Year Born |
| Mr. Dong-Ki Lee Ph.D. | Chief Executive Officer & Director | 0 | 1972 |
| Ms. Young Hye Baek | Executive Director of Legal Affairs | 0 | N/A |
| Ms. Shin Young Park Ph.D. | Executive Vice President of Development Dept. | 0 | N/A |
| Jin Kim Young | Senior Director of Finance Dept. | 0 | N/A |
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
